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458A ABSTRACTS - Special Topics 
Concluelon: CAM therapy was prevalent among our ACS patients with most using CAM 
for symptom relief and leaming about it from their family and fdends, with an average out 
of pocket cost of $92 a month. Given the high prevalence of use and cost, it is essential 
that medical science investigate the efficacy and potential risks of CAM in patients with 
coronary artery disease. 
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1215-163 Underprescr lb lng  Ang io tens in  Conver t ing  Enzyme 
Inhibitors in Heart Failure: A Missed Economic 
Oppor tun i ty  
SteDhania K. Hauser. Marc F. Botteman, Joseph A. Gdcar, Zoe Kopp, Chris L. Pashos, 
Hadan M. Krumholz, Abt Associates Clinical Trials, Cambridge, Massachusetts, Yale 
University School of Medicine, New Haven, ConnecticuL 
Background: Despite demonstrated benefits and recommendations by national guide- 
lines, angiotensin converting-enzyme inhibitors (ACE-I) are underpresoribed in left-van- 
tricular systolic dysfunction (LVSD) and heart failure (HF). The impact of underutilization 
has not been quantified in the United States. Our objective was to estimate the annual 
clinical end economic impact of ACE-I underprescdbing in patients identified as ideal 
candidates for, but not receiving, ACE-I, and the cost effectiveness of prescribing ACE-I 
in these patients. 
Methods: The number of potential candidates not receiving ACE-I was determined from 
the literature, This population was categorized into 3 cohorts corresponding to the popu- 
lations from large prospective studies: symptomatic chronic systolic HF (SOLVD-Type), 
post-myocardial infarction (MI) HF (AIRE-Tybe), and post-MI, asymptomatic LVSD 
(SAVE-Typa). Based on the Uterature, we estimated the economic burden of underpre- 
scdbing ACE-I in terms of excess hospitalizations, direct medical costs (inpatient and 
ACE-I drug costs), deaths, and life-years lost. 
Results: We estimate that more than 280,000 ideal candidates for ACE-I fail to receive 
treatment, of which 187,850 are SOLVD-Type, 60,771 AIRE-Type, and 32,566 SAVE- 
Type. ACE-I use in these patients could potentially prevent 2,217, 2,486, and 436 prema- 
ture deaths, respectively, and save 4,878, 5,469 and 960 years of life annually, respec- 
tively. Similarly, 12,645, 3,403, and 235 hospital stays could be averted annually, 
avoiding $126.6 mil, $34 mil, and $2.4 rail in hospital costs, respectively. Upon inclusion 
of drug cost ($390 per patient per year), ACE-I treatment in these populations was pro- 
jected to result in net cost savings of $53 rail (SOLVD-Type) and $10 rail (AIRE-Type) 
and in a net cost of $10 mil (SAVE-Type) annually. Thus, treating patients in the first two 
groups was projected to save both lives and costs, whereas treating patients in the third 
group was projected to cost $10,800 per life-year saved. 
Conclusion: Treating the estimated 280,000 patients with LVSD or HF who could benefit 
from ACE-I therapy is an economically attractive investment o improve quality of care. 
1215-168 Physician Specialty and Quality of Care for Elderly 
Pat ients  Hosp i ta l i zed  With Heart  Fa i lure 
JoAnna M. Foodv. Salf S, Rathore, Yongfei Wang, Frederick A. Masoudi, Edward P. 
Havranek, Diana L. Ordin, Harlan M. Krumholz, Centers for Medicare and Medicaid 
Services, Yale University School of Medicine, New Haven, Connecticut, Colorodo 
Foundation for Medical Care, Denver, Colorado. 
Background.Whether specialist care is associated with better quality of care remains contro- 
versial.We sought to determine whether attending physician specialty is associated with 
indicators of quality of care among elderly patients hospitalized with heart failure (HF). Meth- 
ods: We studied a national sample of 26,305 Medicare patients age --65 years admitted to a 
hospital with HF in 1998-99 to determine whether the specialty of the attending physician 
was associated with quality of care. Patients were catsgodzed by physician specialty (cardi- 
ologist, internist or family practitioner) and evaluated for the use of 9 quality of care indica- 
tors among patients eligible for treatment with no contrsindicetions. Results: Cardiologists 
were most likely to assess EF dudng hospital stay. In patients in whom EF was shown to be 
low, the rates of presodption of ACE-I did not vary by specialty. Overall rates for counseling 
were low irrespective of specialty, although cardiologists were more likely to counsel regard- 
ing weight monitoring, worsening symptoms, and follow.up, but were less likely to document 
smoking cessation counseling (see Table). Conclusions: In this national sample of older 
patient hospitalized with HF, the specialty of the attending physician was associated with lit- 
tle absolute difference in these 9 process indicators. Irrespective of specialty, significant 
opportunities for improvement exist in the care of older patients with HF. 
Quality Indicator Cardiologist Internist Family Practitioner p 
Assessment of EF 52.3 50.6 45.7 <0.01 
ACE-I at Discharge 80.8 78. f 78.8 0.37 
Dicharge Counseling 
Smoking Cessation 18.5 25.6 24.1 0.11 
Medications 66.6 66.2 63.9 0.13 
Weight Monitoring 10.6 8.2 8.2 <0.01 
Diet 84.1 83.1 82~1 0.23 
Activity Level 77.0 75.3 76.9 0.22 
Follow-up Appointment 92.3 89.8 90.7 <0.01 
Worsening Symptoms 23.5 21.6 20.1 0.03 
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1215-169 Cardiologists Care for a Distinct CIInicel Subset of 
Older Patients Hospitalized With Heart Failure: 
Experience From the National Heart Failure Project 
JoAnna M. Foodv. Self S. Rathore, Yongfei Wang, Frederick A. Masoudi, Diana L. Ordin, 
Hadan M. Krumholz, Centers for Medicare and Medicaid Services, Yale University 
School of Medicine, New Haven, Connecticut, Colorado Foundation for Medical Care, 
Denver, Colorado. 
Background: Little is known about the proportion of older heart failure (HF) patients who 
have a cardiologist as their attending and whether these patients differ from those treated 
by other physicians. 
Methods: We studied 26,159 Medicare patients age >/= 65 years hospitalized with HF in 
1998-99 to determine the proportion of patients treated by cardiologists and to identify 
charactedstics associated with having a cardiologist as an attending. Demographic, clini- 
cal, geographic, and hospital charactedstics were evaluated in a backward stepwise 
polytomous logistic regression model to identify factors associated with cardiologist care 
compared with internist (IM) or family practitioner (FP) care. 
Results: Cardiologists cared for 25.5% of patients while IM and FP cared for 50.0% and 
24.5% of patients. Female patients (OR 0.91, 95%CI 0.83-1.00), older patients (OR 0.92, 
95% CI 0.90-0.95 par each year), and black patients (OR 0.84, 95% CI 0.71-0.99), were 
less likely to have cardiologist care. Patients with COPD (OR 0.70, 95% CI 0.63-0.75), 
dementia (OR 0.59, 95% CI 0.49-0.71), and diabetes (OR 0.79, 95% CI 0,72-0.87)were 
less likely to be treated by a cardiologist, while patients with prior HF (OR 1.15, 95% CI 
1.04-1.27) or coronary disease (OR 1.25, 95% CI 1.11-1,41) were more likely to receive 
cardiologist care. Patients treated in rural areas (OR 0.59, 95% CI 0.50-0.70), in the Mid- 
west (OR 0,71, 95% CI 0,60-0.84 vs Northeast), and in hospitals without cardiac care 
facilities or hospitals with only a cardiac catheterization lab (OR 0.75, 95% CI 0.64-0.88 
and OR 0.65, 95% CI 0.56-0.75 respectively vs with CABG facilities) were less likely to 
be treated by a cardiologist. Patients hospitalized at for-profit hospitals (OR 127, 95% 
C1-1.06-1.51 vs public) were more likely to have a cardiologist as their attending. 
Conclusions: Cardiologists were attandiogs for only one fourth of older patients hospital- 
ized with HF. These patients are younger with less comorbidity than patients cared for by 
either internists or family practitioners. Case mix should be considered when making 
quality of care and outcomes comparisons between specialties. 
1215-170 Impact of Age, Gender, and Race on Quality of Care of 
Elderly Patients With Congeatlve Heart Failure 
Jav K. Amin, Michael J. Lim, Chih-Wen Pal, Gerriann Finnegan, Kim A. Eagle, Rajandra 
H. Mehta, University of Michigan, Ann Arbor, Michigan, Michigan Peer Review 
Organization, Plymouth, Michigan. 
Background: Congestive heart failure (CHF) is more common in the eldedy, females, 
and non-whites in the United States. However, the influence of age, gender, and race on 
the quality of care of CHF patients (pts) has not been extensively studied. 
Method,=: We evaluated 5871 Medicare beneficiaries admitted to 31 acute care hospitals 
in Southeast Michigan with CHF (1/1/98-12/31/98). Patients were identified retrospec- 
tively using ICD-9 codes for CHF. They were divided into 3 age groups: Group A (65 ~ 74 
years), Group B (75 _< 84 years) and Group C (-> 65 years). Quality indicators (in ideal 
patients) were evaluated among different age groups, gender, and race. 
ResultS: The quality care indicators and the impact of age, gender, and race are shown. 
(Table). There were no differences in the length of stay for the different age groups, gen- 
der, or race. One-year mortality was higher in whites compared to non-whites(36.9% vs. 
32.9%, p=. 005) with a trend towards higher 1 -year mortality with increasing age. Gender 
did not influence 1 -year mortality. 
Conclusion: Quality of care is adversely affected by increasing age end female gender 
in hospitalized CHF pts. This data identifies a significant opportunity for improvement in 
the quality of care in these hi~lh-dsk sub~reups that needs to be addressed. 
Quality Group AGroup BGroup C P Male Female P White Non- P 
Indicators n=1751 n=2369 n=1244 Value n=2329 n=3542 Value n=4410 white Value 
n=1461 
Discharge ACE- 80.4 77.6 75.2 0.429 78.1 78.7 0.804 76.0 84.4 0.001 
inhibitor/ARB 
(%) 
LVEF 70.3 69.4 62.1 0.001 70.1 66.5 0.004 68 67.8 0.88 
documented (%) 
Discharge 33 20 10.5 0.10 30.6 22.3 0.157 30.2 22.8 0.21 
smoking 
cessation 
counseling (%) 
Discharge 98.1 97.2 94.9 0.122 96.5 97.8 0.142 96.8 97.B 0.295 
written 
instructions (%) 
Weights 67.3 67.9 55.3 0.003 68.6 63 0.020 66.3 64.8 0.566 
measured, 
>50% hospital 
days (%) 
Discharge 56.4 44.6 28.4 0.002 47.2 44.4 0.575 46.9 42.4 0.448 
wadarin in CHF 
pts with atdal 
fibdllation (%) 
